CIMA delivers technologies to commercialize new drugs and extend the product life cycle of established brands. The company’s drug delivery expertise includes R&D, formulation, manufacturing and packaging. Its range of drug delivery technologies suit various APIs and address product life cycle challenges and include orally disintegrating tablets, taste-masking expertise, oral transmucosal, tamper-deterrent technology, oral granules and powder, customized release profiles and solubilization technology. CIMA is a subsidiary of Teva Pharmaceuticals as part of Teva’s acquisition of CIMA parent company Cephalon Inc.